TP53 and liver cancer: We previously generated a CRISPR‐mediated PTEN and TP53 mutation cynomolgus monkey liver cancer model.[14] The TP53 mutation was significantly related to a poor response to sorafenib in HCC cell lines (Figure3A, data from the Genomics of Drug Sensitivity in Cancer Project, https://www.cancerrxgene.org), and the PTEN mutation was reported as remarkably correlated with immunotherapy resistance.[20, 21, 22, 23] Figure 3B presents a schematic of our in vivo study design.